CareDx (CDNA) Reports Q4 Earnings: What Key Metrics Have to Say

Core Insights - CareDx reported revenue of $108.39 million for the quarter ended December 2025, reflecting a year-over-year increase of 25.2% [1] - The earnings per share (EPS) was $0.12, down from $0.18 in the same quarter last year, indicating a significant decline [1] - The revenue exceeded the Zacks Consensus Estimate by 5.66%, while the EPS fell short by 48.94% compared to the consensus estimate of $0.24 [1] Revenue Breakdown - Revenue from Patient and Digital Solutions was $16.76 million, surpassing the estimated $15.25 million, marking a year-over-year increase of 47.1% [4] - Revenue from Testing Services reached $78.37 million, exceeding the average estimate of $74.95 million, with a year-over-year growth of 22.8% [4] - Revenue from Product sales was $13.26 million, compared to the estimated $12.45 million, representing a year-over-year increase of 16.6% [4] Stock Performance - CareDx shares have declined by 9.7% over the past month, while the Zacks S&P 500 composite experienced a smaller decline of 1% [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]